Redeye provides its first take on Oncopeptides' Q1 report 2026. Sales grew 37% versus Q4 2025. Operating costs amounted to SEK-71m, with an EBIT of SEK-46m. Overall, the quarter was clearly above our (and the market's) expectations and we expect a strong positive share reaction.
LÄS MER
